

Itziar OyagÃ¼ez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3854933/publications.pdf>

Version: 2024-02-01

58
papers

948
citations

516215

16
h-index

525886

27
g-index

80
all docs

80
docs citations

80
times ranked

1191
citing authors

#	ARTICLE	IF	CITATIONS
1	Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, e40-e47.	0.5	6
2	Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain. <i>European Journal of Health Economics</i> , 2022, 23, 551-558.	1.4	10
3	Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 263-277.	0.7	5
4	Cost Analysis of FreeStyle Libre® System in Type 2 Diabetes Mellitus Population. <i>Diabetes Therapy</i> , 2021, 12, 2329-2342.	1.2	4
5	Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus. <i>PharmacoEconomics - Open</i> , 2020, 4, 277-286.	0.9	5
6	Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention. <i>PharmacoEconomics - Open</i> , 2020, 4, 485-497.	0.9	6
7	Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients. <i>BMC Ophthalmology</i> , 2020, 20, 371.	0.6	5
8	Cost analysis of the flash monitoring system (FreeStyle Libre 2) in adults with type 1 diabetes mellitus. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001330.	1.2	19
9	Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain. <i>European Journal of Haematology</i> , 2020, 105, 94-100.	1.1	2
10	Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib. <i>Lung Cancer Management</i> , 2020, 9, LMT28.	1.5	3
11	Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. <i>Clinical Rheumatology</i> , 2020, 39, 2919-2930.	1.0	12
12	1166-P: Cost Analysis of a Flash Glucose Monitoring System in Type 2 Diabetes Receiving 2 Insulin Doses a Day in Spain. <i>Diabetes</i> , 2020, 69, .	0.3	0
13	Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients. <i>Clinical Rheumatology</i> , 2019, 38, 3521-3528.	1.0	6
14	Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. <i>Public Health</i> , 2019, 167, 136-146.	1.4	28
15	THU0048€...2ND LINE TREATMENT WITH LESINURAD AND ALLOPURINOL VERSUS FEBUXOSTAT FOR MANAGEMENT OF HYPERURICEMIA: A COST-EFFECTIVENESS ANALYSIS FOR SPANISH PATIENTS. , 2019, , .		0
16	Budget impact analysis of the XEN® gel stent implant for glaucoma treatment. <i>Expert Review of Ophthalmology</i> , 2019, 14, 5-13.	0.3	5
17	Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment. <i>Clinical Drug Investigation</i> , 2018, 38, 611-620.	1.1	10
18	Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema. <i>Farmacia Hospitalaria</i> , 2018, 42, 244-250.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 750-758.	1.0	10
20	Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B. <i>Annals of Hepatology</i> , 2017, 16, 358-365.	0.6	6
21	Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. <i>BMC Infectious Diseases</i> , 2017, 17, 687.	1.3	26
22	Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 619-626.	0.1	4
23	Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain. , 2017, , .		0
24	Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B. <i>Annals of Hepatology</i> , 2017, 16, 358-365.	0.6	3
25	Análisis de coste-efectividad y coste-utilidad de ingenol mebutato versus diclofenaco 3% e imiquimod 5% en el tratamiento de la queratosis actínica en España. <i>Actas Dermo-sifilográficas</i> , 2016, 107, 498-508.	0.2	6
26	Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 465-477.	1.0	7
27	Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain. <i>Actas Dermo-sifilográficas</i> , 2016, 107, 498-508.	0.2	5
28	Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. <i>Clinical Drug Investigation</i> , 2016, 36, 41-53.	1.1	23
29	Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain. <i>Clinical Drug Investigation</i> , 2016, 36, 479-490.	1.1	5
30	Análisis de costes de la utilización de fármacos biológicos para la artritis reumatoide en primera línea de tratamiento tras respuesta inadecuada a metotrexato en función del peso de los pacientes. <i>Reumatología Clínica</i> , 2016, 12, 123-129.	0.2	5
31	Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism. <i>Farmacia Hospitalaria</i> , 2016, 40, 187-208.	0.6	5
32	Surgical Treatment of Pressure Ulcers with a Fibrin Sealant in Patients with Spinal Cord Injury. <i>Advances in Skin and Wound Care</i> , 2015, 28, 503-507.	0.5	2
33	Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain. <i>International Journal of COPD</i> , 2015, 10, 2027.	0.9	10
34	Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. <i>PLoS ONE</i> , 2015, 10, e0122613.	1.1	2
35	Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain. <i>Haemophilia</i> , 2015, 21, 320-329.	1.0	14
36	Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis. <i>Health Economics Review</i> , 2015, 5, 49.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Situación del tratamiento anticoagulante oral en pacientes con fibrilación auricular no valvular en España. Estudio REACT-AF. Revista Clínica Española, 2015, 215, 73-82.	0.2	20
38	Use of Floseal®, a human gelatine-thrombin matrix sealant, in surgery: a systematic review. BMC Surgery, 2014, 14, 111.	0.6	86
39	Eficiencia de la combinación naproxeno/esomeprazol para el tratamiento de la artrosis en España. Reumatología Clínica, 2014, 10, 210-217.	0.2	14
40	Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B. Pharmacoeconomics, 2013, 31, 63-75.	1.7	15
41	Trabectedin plus PLD versus PLD monotherapy in patients with platinum-sensitive relapsed ovarian cancer: a cost-effectiveness analysis in Spain. European Journal of Hospital Pharmacy, 2012, 19, 364-369.	0.5	2
42	Análisis coste-efectividad de dabigatrán para la prevención de ictus y embolia sistémica en fibrilación auricular no valvular en España. Revista Española De Cardiología, 2012, 65, 901-910.	0.6	76
43	Cost Effectiveness of Prostacyclins in Pulmonary Arterial Hypertension. Applied Health Economics and Health Policy, 2012, 10, 175-188.	1.0	17
44	Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs. Health Economics Review, 2012, 2, 16.	0.8	15
45	Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain. Health Economics Review, 2012, 2, 3.	0.8	5
46	Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Economics Review, 2012, 2, 8.	0.8	28
47	Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain. Revista Española De Cardiología (English Ed), 2012, 65, 901-910.	0.4	39
48	Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain. Clinical and Translational Oncology, 2010, 12, 692-700.	1.2	15
49	Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system. Clinical Therapeutics, 2010, 32, 2232-2245.	1.1	3
50	Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007. Applied Health Economics and Health Policy, 2010, 8, 301-315.	1.0	50
51	Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1. Farmacia Hospitalaria (English Edition), 2009, 33, 247-256.	0.0	1
52	The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: A model-based analysis for Spain. Vaccine, 2007, 25, 6900-6910.	1.7	26
53	Hospitalization by Pneumonia and Influenza in the 50-64 Year Old Population in Spain (1999-2002). Hum Vaccin, 2006, 2, 181-184.	2.4	9
54	Burden of hospitalizations attributable to rotavirus infection in children in Spain, period 1999-2000. Vaccine, 2004, 22, 2221-2225.	1.7	54

#	ARTICLE	IF	CITATIONS
55	The Burden of Severe Varicella in Spain, 1995â€“2000 Period. European Journal of Epidemiology, 2003, 19, 699-702.	2.5	18
56	Hospital admissions for pertussis in Spain, 1995â€“1998. Vaccine, 2001, 19, 4791-4794.	1.7	49
57	Epidemiology of primary varicella hospitalizations in Spain. Vaccine, 2001, 20, 295-298.	1.7	31
58	Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. International Journal of Impotence Research, 2001, 13, 338-347.	1.0	38